Positive impactResults
Motilal Oswal bullish on Granules India, Titan as pharma, jewellery demand stays strong
CNBC-TV18 1 hr ago·11 Sept 2026, 6:01 am
Motilal Oswal has maintained a positive outlook on Granules India, citing strong earnings and robust growth in its complex generics and Contract Development and Manufacturing Organization (CDMO) segments. The firm believes the company is well-positioned to benefit from the global demand for high-quality pharmaceutical ingredients.
For investors, this endorsement highlights Granules India's ability to navigate a competitive market through its diversified business model. The focus on complex generics and CDMO services suggests a strategy that goes beyond simple manufacturing, offering potential for sustained revenue streams.
Investors should watch the company's ability to execute its expansion plans and manage operational costs. Keeping an eye on global pharma demand trends will also be key to understanding the stock's future performance.
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Granules India (GRANULES).
- Category: Results.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Granules India worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
